◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › 0-9 › 0928

King International Investment Limited (0928) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Diagnostics & Research · DATA UPDATED 2026-10-06

King International Investment Limited (0928) operates in the Diagnostics & Research industry and is headquartered in Central, Hong Kong with about 13 employees. Its market capitalization is roughly HK$241 million. In the fiscal year ended 2026-03-31, 0928 reported HK$143M in revenue and HK$2M in net income.

King International Investment Limited, an investment holding company, provides healthcare products and services in the People's Republic of China and Hong Kong.

Interactive charts & full statements → Open the 0928 valuation workbench →

0928 Revenue & Earnings History — Annual Income Statement

Income statement2026-03-312025-03-312024-03-312023-03-312022-03-31
Total RevenueHK$143MHK$41MHK$234MHK$224M—
Gross ProfitHK$25MHK$13MHK$38MHK$12M—
Operating Income (EBIT)HK$9M(HK$13M)HK$18M(HK$32M)—
Net IncomeHK$2M(HK$48M)HK$16M(HK$25M)—

HKD; HK$M / HK$B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

0928 Free Cash Flow History

0928 Balance Sheet History

Balance sheet2026-03-312025-03-312024-03-312023-03-312022-03-31
Total AssetsHK$385MHK$286MHK$336MHK$264M—
Total LiabilitiesHK$147MHK$64MHK$70MHK$31M—

HKD; HK$M / HK$B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 0928 viewer.

Other Companies in Diagnostics & Research

← 0927All “0-9” companies0929 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.